{"schema_version":"secwatch.filing_event.v1","accession":"0001808665-24-000021","form_type":"8-K","ticker":"ASRT","cik":"0001808665","company_name":"Assertio Holdings, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.238995+00:00","generated_at":"2026-06-02T22:18:44.083882+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Assertio Q1 net product sales $31.9M; Rolvedon sales grow to $14.5M; guides FY $110-125M","bullets":["Net product sales of $31.9M in Q1 2024 vs $41.8M in Q1 2023; net loss of $4.5M vs $3.5M loss.","Rolvedon net sales $14.5M, up from $11.0M in Q4 2023, driven by volume growth; same-day dosing trial enrollment completed, data expected year-end.","Indocin net sales $8.7M, down from $10.8M in Q4 2023 due to generic competition.","Adjusted EBITDA (non-GAAP) $7.4M in Q1 2024, up from $4.5M in Q4 2023; SG&A reduced to $18.5M from $24.0M.","FY 2024 guidance reaffirmed: net product sales $110-125M, adjusted EBITDA $20-30M; cash increased to $80.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001808665-24-000021","json":"https://secwatch.observer/filing/0001808665-24-000021.json","markdown":"https://secwatch.observer/filing/0001808665-24-000021.md","text":"https://secwatch.observer/filing/0001808665-24-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808665/000180866524000021/0001808665-24-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808665/000180866524000021/asrt-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:18:44.083882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"43465b0c004c86322d105266b5080f092ec1d48e","claim":"Assertio Holdings, Inc. updated its three months ended March 31, 2024 guidance (reaffirmed).","evidence_excerpt":"On May 6, 2024, Assertio Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808665/000180866524000021/0001808665-24-000021-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}